We then reviewed cross-sectional surveys, early-phase trials, and large-scale phase II and II clinical trials that reported HRQL measures in cancer patients receiving PD-1, PD-L1, or CTLA-4 inhibitors. This evidence concerns the gene CTLA4 and cancer.